08.02.2013 - The EU’s IMI has launched a novel platform for drug screening. It is aimed at screening 500,000 compounds to find new lead structures.
Under the umbrella of the European Lead Factory, an international consortium of 30 partners led by German Bayer Pharma AG and Taros Chemicals GmbH & Co KG will screen 300,000 compounds provided by seven pharma companies: Bayer, AstraZeneca AB, H. Lundbeck A/S, and Janssen Pharmaceutica NV, Merck KGaA, Sanofi, and UCB Pharma SA. Additionally, the academic and SMEs will synthesise a library of 200,000 completely novel compounds. The pharma companies will screen this new chemical space.
Additionally, the academic and SME partners will screen the compound library with their own assays generating new IP within a newly established European Screening Centre. The EU will fund the project with €80m. The Joint European Compound Collection will be accessible to all project partners and to public organisations offering promising new targets for drug discovery screening.
„The seven EFPIA partners will, for the first time, open their compound libraries for public researchers“, Taros’ CEO Dr Dimitrios Tzalis told EuroBiotechNews. „This open access approach is a novelty and may lead to significant progress in the field of drug development.“ Hanno Wild, Senior VP and Head of Candidate Generation & Exploration at Project Coordinator Bayer HealthCare Global Drug Discovery, says: ‘The European Lead Factory is an outstanding example of a project in which public-private partnerships enable collaborative drug discovery.“ The Innovative Medicines Initiave is a industry-driven Public Private Partnership between the European Commission and the EU pharma association EFPIA that aims to boost productivity of drug development.
20.07.2016 Belgian molecular diagnostics company Biocartis Group NV has raised €55m and will use the funds mainly to expand manufacturing capacities for its PCR-based molecular diagnostics system Idylla.
19.07.2016 It is Europe’s first gene therapy company to float on Euronext: Gensight raised €40m in its IPO. And it is not the only French company that has taken the leap in an uncertain market climate – Alzheimer’s expert Pharnext also went public.
18.07.2016 When NASA blasted off to the International Space Station on Monday morning, it had UK tech on board. A miniature DNA sequencer from Oxford Nanopore will be used to keep an eye on the ISS atmosphere – and may even analyse alien DNA one day.
13.07.2016 Cell Medica has acquired Swiss antibody specialist Delenex Therapeutics. The deal nets the British cellular therapeutics developer Delenex’ proprietory antibody fragment platform Pentrabody.
12.07.2016 Vienna-based vaccine specialist Themis Bioscience GmbH has secured broad access to a promising virus vaccine vector tech by extending its license agreement with French Institut Pasteur. Its goal: to develop a Zika vaccine.
07.07.2016 Californian biopharma Medivation has agreed to confidential negotiations with its suitors, in particular the French pharmaceutical company Sanofi, which aggressively has buffeted the cancer therapy specialist for months.
06.07.2016 The European Commission started an investigation into Illumina’s and Sequenom’s 2014 patent agreement, UK-competitor Premaitha Health said. The two US companies had agreed to pool their Noninvasive Prenatal Testing IP.
04.07.2016 Cinfa Biotech is shuffling for position on the lucrative biosimilar market. The Spanish-German company has published positive results in a study for a pegfilgrastim copycat with 172 healthy volunteers in Germany.
30.06.2016 UK’s Heptares Therapeutics and Paul Scherrer Institute spinoff leadXpro will collaborate to find new approaches for the determination of high-res X-ray structures of G protein-coupled receptors to find new drugs.
Merck’s advanced water purification system with new high-throughput line delivers up to 9,000 liters of pure water daily with real-time monitoring and ensures constant water quality with low and predictable running costs. more